| Literature DB >> 31648289 |
Valerie Smith1, Louise Gallagher1, Margaret Carroll1, Kathleen Hannon1, Cecily Begley1.
Abstract
Concern has been expressed globally over rising caesarean birth rates. Recently, the International Federation of Gynaecology and Obstetrics (FIGO) called for help from governmental bodies, professional organisations, women's groups, and other stakeholders to reduce unnecessary caesareans. As part of a wider research initiative, we conducted an overview of systematic reviews of antenatal and intrapartum interventions, and reports of evidence based recommendations, to identify and highlight those that have been shown to be effective for reducing caesarean birth, promoting vaginal birth and reducing fear of childbirth. Following registration of the review protocol, (PROSPERO 2018 CRD42018090681), we searched The Cochrane Database of Systematic Reviews, PubMed, CINAHL and EMBASE (Jan 2000-Jan 2018) and searched for grey literature in PROSPERO, and on websites of health professional and other relevant bodies. Screening and selection of reviews, quality appraisal using AMSTAR-2, and data extraction were performed independently by pairs of at least two reviewers. Excluding reviews assessed as 'critically low' on AMSTAR-2 (n = 54), 101 systematic reviews, and 10 reports of evidence based recommendations were included in the overview. Narrative synthesis was performed, due to heterogeneity of review methodology and topics. The results highlight twenty-five interventions, across 17 reviews, that reduced the risk of caesarean, nine interventions across eight reviews that increased the risk of caesarean, eight interventions that reduced instrumental vaginal birth, four interventions that increased spontaneous vaginal birth, and two interventions that reduced fear of childbirth. This overview of reviews identifies and highlights interventions that have been shown to be effective for reducing caesarean birth, promoting vaginal births and reducing fear of childbirth. In recognising that clinical practices change over time, this overview includes reviews published from 2000 onwards only, thus providing contemporary evidence, and a valuable resource for clinicians when making decisions on practices that should be implemented for reducing unnecessary caesarean births safely. Protocol Registration: PROSPERO 2018 CRD42018090681. Available from: http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42018090681.Entities:
Mesh:
Year: 2019 PMID: 31648289 PMCID: PMC6812784 DOI: 10.1371/journal.pone.0224313
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Search terms.
| pregnant OR primigravida OR multigravida OR nulliparous OR obstetrician OR physician OR clinician OR doctor OR doctors OR midwife OR midwives OR “obstetric nurse” OR consultant OR Midwifery | |
| antenatal OR prenatal OR labour OR labor OR intrapartum | |
| caesarean OR cesarean OR “caesarean section” OR “vaginal birth after caesarean” OR VBAC OR “next birth after caesarean” OR “trial of labor” OR “trial of labour” OR TOL OR TOLAC OR “spontaneous vaginal birth” OR ventouse OR forceps OR “instrumental birth” OR “fear of childbirth” OR tocophobia OR tokophobia | |
| “systematic review” OR meta-analysis OR meta-synthesis OR “literature review” OR “clinical guideline” OR “practice guideline” OR “practice recommendation” |
Fig 1Search and selection flow diagram.
Clinical topics across the included reviews that reported on caesarean birth.
| Induction of labour (IOL), third trimester cervical ripening or augmentation of labour | 25 |
| Methods of fetal surveillance (e.g. FHR monitoring, ultrasound in pregnancy, fetal movement counting) | 14 |
| Prevention or treatment of gestational diabetes mellitus (GDM) | 10 |
| Pharmacological, non-pharmacological, and alternative or complementary methods for pain relief in labour (e.g. Epidural, TENS, hypnosis, acupressure) | 9 |
| Oral supplements (e.g. Vitamin C, Vitamin D, Zinc) | 6 |
| Preventing or treating preterm birth | 6 |
| Types of or alternative methods for delivering antenatal care | 6 |
| Antenatal or intrapartum support (e.g. continuous one-to-one care in labour, additional social support) | 3 |
| External cephalic version | 3 |
| Pre-eclampsia | 3 |
| Amnioinfusion | 2 |
| Information about caesarean birth | 2 |
| Antenatal pelvimetry | 1 |
| Birth settings | 1 |
| Fundal pressure in the second stage of labour | 1 |
| Immersion in water | 1 |
| Manual rotation for malposition | 1 |
| Non-clinical interventions for reducing unnecessary caesarean birth | 1 |
| Partogram | 1 |
| Pre-labour rupture of membranes at term | 1 |
| Weight gain during pregnancy | 1 |
Interventions shown to reduce rates of caesarean birth.
| Alfirevic 2014 | Oral misoprostol for IOL versus placebo/no treatment in pregnant women | RR 0.72 (0.54 to 0.95), 8 trials, n = 1029 |
| Alfirevic 2016 | All pharmacological (all routes and doses), mechanical and complementary methods used for IOL versus placebo/no intervention in pregnant women carrying a viable fetus and who are eligible for any method of third-trimester cervical ripening or IOL | 586 trials, n = 96771 |
| Bohren 2017 | Continuous, one-to-one intrapartum support versus usual care in any birth setting | RR 0.75 (0.64 to 0.88), 24 trials, n = 15347 |
| Cluver | Interventions to facilitate ECV at term versus placebo/no intervention | Beta stimulants RR 0.77 (0.67 to 0.88), 6 trials, n = 742; Tocolytics in nulliparous RR 0.85 (0.75 to 0.97), 2 trials, n = 170 |
| Dodd | Progestogen by any route (IV, IM, oral or vaginal) for the prevention of preterm birth versus placebo or no treatment | Vaginal progesterone RR 0.93 (0.88 to 0.98), 6 trials, n = 2143 |
| East | Use of fetal pulse oximetry (FPO) with or without concurrent use of conventional fetal monitoring versus conventional only (no pulse oximetry) in women in labour where fetal monitoring is clinically indicated | FPO and CTG vs CTG only from 36 weeks; FBS prior to study entry RR 0.44 (0.24 to 0.81), 1 trial, n = 146 |
| Gulmezoglu 2012 | Labour induction versus expectant management in pregnant women at or beyond term at low risk for complications | All women RR 0.89 (0.81 to 0.97), 21 trials, n = 8749; 41 weeks RR 0.74 (0.58 to 0.96), 4 trials, n = 998; Cervix unfavourable RR 0.88 (0.80 to 0.98), 8 trials, n = 5051 |
| Hapangama 2009 | Mifepristone for third trimester cervical ripening or IOL versus placebo/no treatment in pregnant women due for third trimester IOL carrying a viable fetus | Mifepristone all doses RR 0.74 (0.60 to 0.92), 9 trials, n = 1043 |
| Hodnett 2010 | Standardized or individualized programs of additional social support versus usual care for pregnant women believed at high risk for giving birth to babies that are either preterm or weigh less than 2500 gm, or both, at birth | RR 0.87 (0.78 to 0.97), 9 trials, n = 4522 |
| Hofmeyr 2012b | Amnioinfusion (AI) versus no AI in women whose babies were considered to be at increased risk of, or had FHR patterns suggestive of, umbilical cord compression in labour | Transcervical AI RR 0.62 (0.46 to 0.83), 13 trials, n = 1493; CS for suspected fetal distress RR 0.46 (0.31to 0.68), 12 trials, n = 1588 |
| Hofmeyr 2014 | Amnioinfusion for meconium-stained liquor in labour versus no amnioinfusion in women in labour with moderate or thick meconium staining of the amniotic fluid | RR 0.59 (0.41 to 0.84), 3 trials, n = 1137 (limited peripartum surveillance) |
| Hofmeyr 2015 | ECV versus no ECV in pregnant women with babies in the breech presentation at or near term | RR 0.57 (0.40 to 0.82), 8 trials, n = 1305 |
| Kavanagh 2006 | Hyaluronidase versus placebo/no treatment for third trimester cervical ripening or IOL in pregnant women due for third trimester induction of labour, carrying a viable fetus | All women RR 0.37 (0.22 to 0.61), 1 trial, n = 168; Primiparae RR 0.43 (0.23 to 0.81), 1 trial, n = 94; Multiparae RR 0.28 (0.12 to 0.67), 1 trial, n = 74; Women with previous caesarean RR 0.35 (0.15 to 0.81), 1 trial, n = 29 |
| Lavender 2013 | Labour management using a partogram versus no partogram in women with singleton pregnancies, cephalic in spontaneous labour at term | Low-resource setting RR 0.38 (0.24 to 0.61), 1 trial, n = 434 |
| Smith | Complementary and alternative therapies used in labour (but not biofeedback) with or without concurrent use of pharmacological or non-pharmacological interventions versus placebo or no treatment in women in spontaneous or induced labour, for pain management in labour | Hypnosis RR 0.46 (0.30 to 0.72), 1 trial, n = 520 |
| Smith 2011a | Acupuncture or acupressure versus placebo, no treatment for pain management in labour | Acupressure RR 0.24 (0.11 to 0.54), 1 trial, n = 120 |
| Wei | Early augmentation with amniotomy and oxytocin versus conservative form of management in pregnant women in spontaneous labour | Prevention studies RR 0.87 (0.77 to 0.99), 11 trials, n = 7753 |
*See S1 File for full references to the reviews
Interventions shown to increase rates of caesarean birth.
| Alfirevic 2009 | Intravenous oxytocin alone for third trimester cervical ripening or IOL versus placebo /expectant management in pregnant women | RR 1.17 (1.01 to 1.35), 24 trials, n = 6620 |
| Alfirevic 2017 | Continuous CTG during labour versus no fetal monitoring or IA with Pinard stethoscope or hand-held Doppler ultrasound device | CTG versus IA: All women RR 1.63 (1.29 to 1.33), 11 trials, n = 18861; High-risk women RR 1.91 (1.39 to 2.61), 6 trials, n = 2069; Low-risk women RR 2.06 (1.24 to 3.45), 2 trials, n = 1431 |
| Bond | Planned early birth (IOL or CS) versus expectant management for women with preterm pre-labour rupture of the membranes between 24 and 37 weeks’ gestation | RR 1.26 (1.11 to 1.44), 12 trials, n = 3620 |
| Dodd | Antenatal care specifically designed for women with a multiple pregnancy versus usual care | RR 1.38 (1.06 to 1.81), 1 trial, n = 162 |
| Martis | IA during labour versus another method of IA in pregnant women | Intermittent CTG versus Pinard |
| Pattinson 2017 | Pelvimetry versus no pelvimetry in pregnant women with a singleton, cephalic presentation fetus who have or have not had a previous caesarean section | All women RR 1.34 (1.19 to 1.52), 5 trials, n = 1159; Women with no previous caesarean RR 1.24 (1.02 to 1.52), 3 trials, n = 769; Women with previous caesarean RR 1.45 (1.26 to 1.67), 2 trials, n = 390 |
| Stock | Immediate delivery versus deferred delivery for a set period of time, until test results worsen, or expectant management in pregnant women at > 36 weeks’ in whom there is clinical suspicion of fetal compromise | RR 1.15 (1.07 to 1.24), 1 trial, n = 547 |
| Till | Direct incentives explicitly linked to initiation and frequency of prenatal care (e.g. cash, vouchers, coupons or products not generally offered to patients as a standard of prenatal care) versus no incentives to increase utilization of timely prenatal care among pregnant women | RR 1.97 (1.18 to 3.30), 1 study, n = 979 |
*See S1 File for full references to the reviews
Interventions shown to affect adverse effects positively or negatively.
| Bond | Planned early birth (IOL or CS) versus expectant management for women with PPROM 24 and 37 weeks’ gestation | Neonatal death RR 2.55 (1.17 to 5.56), 11 trials, n = 3316 |
| Dowswell 2015 | Antenatal care programmes with reduced visits for low-risk women with standard/usual care | Perinatal death RR 1.15 (1.01 to 1.32), 3 cluster trials |
| Grivell | Antenatal CTG (both traditional and computerised assessments) in improving outcomes for pregnant women and their babies | Perinatal death RR 0.20 (0.04 to 0.88) 2 trials, n = 469 |
| Gulmezoglu 2012 | Policy of IOL at term or post-term compared with awaiting spontaneous labour or later IOL in pregnant women at or beyond term at low risk for complications | Perinatal death RR 0.31 (0.12 to 0.81), 17 trials, n = 7407 |
| Hapangama 2009 | Mifepristone for third trimester cervical ripening or IOL versus placebo/no treatment in pregnant women due for third trimester IOL carrying a viable fetus | Maternal adverse effects RR 1.51 (1.06 to 2.15), 4 trials, n = 734 |
| Hofmeyr 2014 | Amnioinfusion for meconium-stained liquor versus no amnioinfusion in women in labour with moderate or thick meconium staining of the amniotic fluid | Perinatal death RR 0.35 (0.18 to 0.66), 10 trials, n = 3913 |
Interventions shown to affect satisfaction positively or negatively.
| Alfirevic | Intravenous oxytocin alone versus placebo/expectant management for third trimester cervical ripening and IOL | Women were less likely to be dissatisfied with IOL compared with expectant management; 5.9% versus 13.7%, RR 0.43 (0.33 to 0.56), 1 trial, n = 5041 |
| Bohren | Continuous, one-to-one intrapartum support versus usual care | Negative feelings about birth experience |
| Cluver | Interventions to facilitate ECV versus placebo | Systemic opioids RR 2.60 (1.25 to 3.95), 1 trial, n = 60 |
| Dowswell | Provision of a schedule of reduced number of visits, with or without goal-oriented antenatal care versus usual care in low-risk pregnant women attending ANC | Satisfied with quality of prenatal care MD -0.20 (-0.28 to -0.11), 2 trials, n = 2198, and would choose same schedule in future (yes) RR 1.12 (1.05 to 1.20), 1 trial, n = 1862 |
| Dowswell | TENS (any model or type) versus placebo TENS or routine care on pain in labour | TENS to acupoints RR 4.1 (1.81 to 9.29), 1 trial, n = 90 |
| Dowswell | Antenatal day care: admission and discharge home with no overnight stay | “I am satisfied with the care I received” (number disagreeing or not sure) RR 0.40 (0.18 to 0.88), 1 trial, n = 350 |
| Hodnett | Alternative institutional birth setting | Very positive views of care RR 1.96 (1.78 to 2.15), 2 trials, n = 1207 |
| Kobayashi | Assessment programmes in early labour versus no intervention or usual care for low risk women during early labour | MD 16.00 (7.53 to 24.47), 1 study, n = 201 |
| Khunpradit | Directed interventions versus usual care non-clinical interventions for reducing unnecessary caesarean section rates. | Decision analysis Adj diff 0.14 (0.02 to 0.27) P = 0.022 |
| Smith | Relaxation techniques versus placebo/no treatment/usual care for pain management in labour | RR 8.0 (1.10 to 58.19), 1 trial, n = 40 |
| Whitworth | Routine US versus selective US Women with early pregnancies, i.e. less than 24 weeks’ gestation | Mother not satisfied with care RR 0.80 (0.65 to 0.99), 1 trial, n = 634 |